Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311845 | 0.88 | SPR (0.41) | TSHRSPRFAAHHSD17B10ALDH1A1 | |
| SCHEMBL8326097 | 0.83 | TSHR (0.54) | TSHRSPRFAAHMEN1KMT2A | |
| SCHEMBL14415975 | 0.83 | TSHR (0.45) | TSHRFAAHMEN1KMT2AALDH1A1 | |
| SCHEMBL2730627 | 0.83 | SPR (0.49) | TSHRSPRFAAHMEN1KMT2A | |
| SCHEMBL22837680 | 0.83 | TSHR (0.43) | TSHRSPRFAAHMEN1KMT2A | |
| SCHEMBL10311846 | 0.81 | TSHR (0.59) | TSHRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7786356 | 0.81 | FAAH (0.55) | TSHRSPRFAAHMEN1KMT2A | |
| SCHEMBL8537389 | 0.81 | FAAH (0.55) | TSHRSPRFAAHMEN1KMT2A | |
| SCHEMBL12037854 | 0.81 | FAAH (0.36) | TSHRFAAHMEN1KMT2AHSD17B10 | |
| SCHEMBL13130099 | 0.78 | FAAH (0.56) | TSHRFAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714419-B2 | PEGylated tyrosyl-tRNA synthetase polypeptides | ATYR PHARMA, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20150159148-A1 | PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES | ATYR PHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8927488-B2 | Pegylated C-peptide | CEBIX, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140255378-A1 | PEGYLATED TYROSYL-TRNA SYNTHETASE POLYPEPTIDES | ATYR PHARMA, INC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20120220542-A1 | PEGYLATED C-PEPTIDE | CEBIX, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120178676-A1 | PEGYLATED C-PEPTIDE | CEBIX, INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150159148-A1 | PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES | AARS1, GARS1, DARS1 | TSHR 554/4885SPR 563/4885FAAH 2167/4885 |
| US-20120220542-A1 | PEGYLATED C-PEPTIDE | LNPEP, NGLY1, PRCP | TSHR 991/4885SPR 2048/4885FAAH 2868/4885 |
| US-20120178676-A1 | PEGYLATED C-PEPTIDE | LNPEP, NGLY1, PRCP | TSHR 991/4885SPR 2048/4885FAAH 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.